Nov 2026· Current Hematologic Malignancy Reports· Vol 21· 0 citations· 85 references
Medicine
TL;DR
Current evidence on how social determinants of health can influence multiple aspects of leukemia biology and outcomes is summarized and a framework to address the influence of SDOH along the continuum of acute leukemia care is provided.
Abstract
Acute leukemia outcomes have conventionally been predicated on the genomic characteristics of leukemia cells. However, emerging evidence from population-based and national co-operative group studies suggests a pivotal role of social determinants of health (SDOH) on acute leukemia survival outcomes. Acute leukemia outcomes over the past two decades have benefited from advances in molecular diagnostics, which have ushered in a multitude of targeted therapies including small molecule inhibitors and immunotherapies, liberalization of donor matching for transplantation, and early incorporation of supportive care. However, these advances have not benefited all populations equally. Environmental exposures, insurance status, access to transportation, and language barriers are some evaluable domains of social determinants of health (SDOH) that have been linked to leukemia outcomes. SDOH can influence leukemia outcomes through impact on patient access to specialized care, clinical trial enrollment, allogeneic stem cell transplantation, and palliative care. Beyond well-established disparities in access to care, emerging epidemiologic evidence suggests that SDOH may influence the genomic and biological characteristics of leukemia. Clinical prognostic leukemia models such as ELN 2022 do not accurately predict chemotherapy outcomes in diverse patient populations. This may be attributable to biologic differences in leukemia conferred by the social and heritable aspects of race. With the current landscape shifting to incorporate small-molecule inhibitors and immunotherapies into the frontline treatment of leukemia, SDOH-informed risk stratification can optimize prognostication and guide vulnerable patients toward less toxic, equally effective therapeutic alternatives. This review summarizes current evidence on how social determinants of health can influence multiple aspects of leukemia biology and outcomes and provides a framework to address the influence of SDOH along the continuum of acute leukemia care.
Cancer is a leading global health concern, responsible for significant morbidity and mortality. However, treatment outcomes are not solely determined by biological factors but are heavily influenced by social determinants of health (SDOH), including economic status, geographic location, and racial and ethnic background...
Mary Oyeleke, M. Owusu, Rasheed Yusuf· Journal of Medicine, Physiol...· 0 citations
In this single-institution cohort, children from very low opportunity neighborhoods experienced inferior survival after HCT for acute leukemia in exploratory analyses, and neighborhood opportunity should be investigated in larger, multi-institutional cohorts as a clinical risk factor for poor outcomes.
Katherine T. Lind, Cheng-Chang Wu, A. Nicklawsky et al.· Transplantation and Cellular...· 0 citations
234
Background:
Social determinants of health (SDOH) can have deleterious impact on lung cancer outcomes. Individually, SDOH increase progression risk, but their cumulative impact has not been well studied. We examined the combined and cumulative impact of SDOH on lung cancer progression and mortality.
Methods...
Amir Mehdizadeh-Shrifi, F. Lennartz, Tabea Fröhlich et al.· JCO Oncology Practice· 0 citations
Advances in treatment for hematologic malignancies have created a rapidly growing population of long-term survivors who carry a substantial and compounding burden of treatment-related late effects. As survival rates improve across leukemias, lymphomas, and multiple myeloma, the healthcare system faces increasing pressu...
Shefali Pati, Indushekar Manjunatha, T. Allen et al.· Discover Public Health· 0 citations
Childhood cancer remains one of the leading causes of death from disease among children Despite novel therapeutic options and improved risk stratification over the past several decades, substantial racial and ethnic disparities in outcome persist. The Patient Protection and Affordable Care Act (ACA) sought to imp...
Jinhee Cha, Helen M. Parsons, Logan G. Spector et al.· Cancer Epidemiology, Biomark...· 0 citations
INTRODUCTION
Socioeconomic inequalities in cancer outcomes persist across many high-income countries, including those with universal healthcare systems. Evidence suggests that patients from more deprived populations may experience differences in access to cancer treatment and diagnostic pathways. This study examined so...
B. Pickwell-Smith, L. Paton, I. Soyiri et al.· Cancer Epidemiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.